Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

dMMR Colorectal Cancer Clinical Trial

Official title:
A Phase II Trial of Cadonilimab in Locally Advanced Stage II/III MSI-H/dMMR Colorectal Cancer

Status Recruiting

Clinical Trial Summary

This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05815290
Study type	Interventional
Source	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact	Aiping Zhou, M.D.
Phone	86-10-87788800
Email	zhouap1825@126.com
Status	Recruiting
Phase	Phase 2
Start date	March 29, 2023
Completion date	March 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06262581` - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery	Phase 2
Recruiting	`NCT05239546` - Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers	Phase 2
Recruiting	`NCT06414304` - Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Active, not recruiting	`NCT04301557` - PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer	Phase 2
Terminated	`NCT04244552` - A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies	Phase 1
Not yet recruiting	`NCT06152523` - Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer	Phase 2